The man is enrolled in the BrainGate2 clinical trial at UC Davis Health. His ability to communicate through a computer has ...
1don MSN
New ALS treatment target identified: STAUFEN-1 protein reduction protects brain cells from death
University of Utah researchers at the Pulst-Scoles Laboratory have discovered that reducing levels of the STAUFEN-1 protein ...
The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS ...
A new international study led by researchers from UNSW Sydney's Center for Healthy Brain Aging (CHeBA) has developed the ...
The FDA has granted fast track designation to a vectorized antibody that targets RNA-binding proteins characteristic of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback